"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
(Generic versions may still be available.)
Metrodin® (urofollitropin for injection) is a preparation of gonadotropin extracted from the urine of postmenopausal women. Each ampule of Metrodin® (urofollitropin for injection) contains 75 or 150 IU of follicle-stimulating hormone (FSH) activity, in not more than 0.83 mg (75 IU) or 1.66 mg (150 IU) of extract, plus 10 mg lactose in a sterile, lyophilized form. Metrodin® (urofollitropin for injection) is administered by intramuscular injection.
Metrodin® (urofollitropin for injection) contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity in terms of the Second International Reference Preparation for Human Menopausal Gonadotropins established in September, 1964 by the Expert Committee on Biological Standards of the World Health Organization. Negligible amounts (less than 1 IU per 75 IU FSH) of luteinizing hormone (LH) activity are contained in Metrodin® (urofollitropin for injection) .
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Metrodin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.